Helen I. Torley

2018

In 2018, Helen I. Torley earned a total compensation of $5.8M as President and Chief Executive Officer at Halozyme Therapeutics, a 12% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$831,665
Option Awards$2,115,631
Salary$725,000
Stock Awards$2,115,640
Other$11,733
Total$5,799,669

Torley received $2.1M in stock awards, accounting for 36% of the total pay in 2018.

Torley also received $831.7K in non-equity incentive plan, $2.1M in option awards, $725K in salary and $11.7K in other compensation.

Rankings

In 2018, Helen I. Torley's compensation ranked 1,640th out of 14,244 executives tracked by ExecPay. In other words, Torley earned more than 88.5% of executives.

ClassificationRankingPercentile
All
1,640
out of 14,244
89th
Division
Manufacturing
583
out of 5,765
90th
Major group
Chemicals And Allied Products
182
out of 2,128
91st
Industry group
Drugs
145
out of 1,817
92nd
Industry
Biological Products, Except Diagnostic Substances
35
out of 339
90th

Pay ratio

Helen I. Torley's Pay$5,799,669
Median Employee's Pay$199,899
Pay Ratio

29

to 1

In 2018, the annual total compensation of Helen I. Torley was $5,799,669.

The annual total compensation of the median employee at Halozyme Therapeutics was $199,899.

The ratio of Helen I. Torley's pay to the pay of median employee was therefore 29 to one.

Source: SEC filing on March 22, 2019.

Torley's colleagues

We found four more compensation records of executives who worked with Helen I. Torley at Halozyme Therapeutics in 2018.

2018

Benjamin Hickey

Halozyme Therapeutics

Senior Vice President and Chief Commercial Officer

2018

Laurie Stelzer

Halozyme Therapeutics

Chief Financial Officer

2018

Harry Leonhardt

Halozyme Therapeutics

General Counsel

2018

Dimitrios Chondros

Halozyme Therapeutics

Chief Medical Officer

News

You may also like